What's Happening Now is a quick, thoughtful, real-time briefing regarding material events in the stem cell industry...definitely not the usual stream of insignificant press releases. The most current Happenings are boxed on the left-hand side of most pages on this site. Feel free to use this page to explore the archive of all past Happening items, and subscribe to the RSS feed to stay on top of the events that move the market and the industry.
Pluristem Phase 1/2 Muscle Repair Trial Meets Efficacy Goals
Jan 22, 2014
achievement of efficacy goals (improved muscle contraction force and muscle volume) for its Phase 1/2 trial of placental stem cells in gluteal muscle repair. With PSTI shares having risen steadily since December in anticipation, share price was little changed on the news.
Pluristem Gains Israeli Approval For Trial
Oct 4, 2013
Israel-based (but U.S. incorporated) Pluristem
(PSTI) has received
government approval to include Israeli sites in its current Phase 2 trial
of PLX-PAD cells for intermittent claudication. The approval allows the company to add sites in Israel to the trial's current sites in Germany and the U.S.
FDA Lifts Hold On Pluristem Trial
Sep 16, 2013
The FDA has lifted
the clinical hold on Pluristem
's (PSTI) Phase 2 intermittent claudication trial
, imposed last June due to an adverse event.
Pluristem partner launches Korean intermittant claudication trial
Jul 8, 2013
it's Korean strategic partner, Cha Bio&Diostech, has filed its first clinical trial application for Pluristem's PLX-PAD cells in intermittent claudication (IC) in South Korea, mirroring Pluristem's ongoing Phase II IC clinical trial in the United States.
Pluristem dives on trial hold
Jun 4, 2013
shares were down sharply this morning following news
that the FDA had placed a hold on its clinical trial for calf pain symptoms after a patient experienced an acute allergic reaction following treatment.
Pluristem (PSTI) aims at tendon repair
Apr 23, 2013
late last week its intention to explore sports medicine applications of its PLX-PAD cells in an intended Phase 1 tendon repair study. The news had no immediate impact on its shares' continuing 8-month decline.
Pluristem (PSTI) Advances Gluteal Repair Trial to Phase 2
Apr 8, 2013< Previous Page
| Next Page >